Pharmacokinetics and effect of food on the bioavailability of orally administered venlafaxine

Journal of Clinical Pharmacology

Volumn 37, Issue 10, 1997, Pages 954-961

  Troy, Steven M ^a   Parker, Vernon P ^a   Hicks, David R ^a   Pollack, Gary M ^b   Chiang, Soong T ^a  

^a WYETH AYERST RESEARCH   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VENLAFAXINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; FOOD INTAKE; HUMAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

EID: 0030784436     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04270.x     Document Type: Article

References (19)

1. Moyer JA, Muth EA, Haskins JT, Lappe RW, Sigg EB: In vivo antidepressant profiles of the novel bicyclic compounds Wy-45,030 and Wy-45,881. Soc Neurosci 1984;10:261.
2. Haskins JT, Moyer JA, Muth EA, Sigg EB: Desipramine, Wy-45030, Wy-45881 and ciramadol inhibit locus coeruleus neuronal activity. Eur J Pharmacol 1985;115:139-146.
3. Muth EA, Haskins JT, Moyer JA, Husbands GEM, Nielsen ST, Sigg EB: Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986;35:4493-4497.
4. Rudorfer MV, Potter WZ: Antidepressants: a comparative review of the clinical pharmacology and therapeutic use of the "newer" versus the "older" drugs. Drugs 1989;37:713-738.
5. Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GE: Biochemical, neurophysiological and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 1991;23:191-199.
6. Fabre LF, Putman HP. An ascending single-dose tolerance study of Wy-45,030, a bicyclic antidepressant, in healthy men.: Curr Ther Res 1987;42:901-909.
7. Goldberg HL, Finnerty R: An open-label, variable-dose study of Wy-45,030 (venlafaxine) in depressed outvolunteers. Psychopharmacol Bull 1988;24:198-199.
8. Schweizer E, Clary C, Weise C, Rickels K: An open-label, dose-finding study of Wy-45,030, a novel bicyclic antidepressant. Psychopharmacol Bull 1988;24:195-197.
9. Howell SR, Husbands GEM, Scatina JA, Sisenwine SF: Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 1993;23:349-359.
10. Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST: Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol 1992;32:716-724.
11. Hicks DR, Wolaniuk D, Russell A, Cavanaugh N, Kraml M: A high-performance liquid chromatographic method for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in biological fluids. Ther Drug Monit 1994;16:100-107.
12. Schuirmann DJ: A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987;15:657-680.
13. Boxenbaum H: Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. J Pharmacokinet Biopharm 1980;8:165-176.
14. Mojaverian P, Ferguson RK, Vlasses PH, Rocci ML Jr, Oren A, Fix JA, Caldwell LT, Gardner C: Estimation of gastric residence time of the Heidelberg capsule in humans: effect of varying food composition. Gastroenterology 1985;89:392-397.
15. Bateman DN: Effects of meal temperature and volume on the emptying of liquid from the human stomach. J Physiol 1982;331: 461-467.
16. Bachrach WH: Physiology and pathologic physiology of the stomach. Ciba Clin Symp 1959;11:1-28.
17. Rocci ML Jr, Mojaverian P, Davis RJ, Ferguson RK, Vlasses PH: Food-induced gastric retention and absorption of sustained-release procainamide. Clin Pharmacol Ther 1987;42:45-49.
18. Mojaverian P, Rocci ML Jr, Conner DP, Ahrams WB, Vlasses PH: Effect of food on the absorption of enteric-coated aspirin: correlation with gastric residence time. Clin Pharmacol Ther 1987;41:11-17.
19. Welling PG, Lyons LL, Craig WA, Trochta GA: Influence of diet and fluid on bioavailability of theophylline. Clin Pharmacol Ther 1975;17:475-480.